[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M: Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer; 2002 Jan 15;94(2):492-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
  • BACKGROUND: Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) combined with cytoreductive surgery (CS) has been proposed as a new multimodal treatment mainly for carcinomatosis of gastrointestinal origin.
  • To evaluate whether this regimen could be used for other tumor types, the authors conducted a Phase I study on HIIC with doxorubicin and cisplatin in patients with peritoneal carcinomatosis or sarcomatosis.
  • PATIENTS AND METHODS: Thirty-one patients with peritoneal carcinomatosis or sarcomatosis (PCS) were enrolled for the study.
  • After completion of CS, HIIC was administered with drug doses that were increased for each consecutive cohort following a three-patient cohort scheme.
  • Drug pharmacokinetics and procedure costs also were analyzed.
  • The perfusate/plasma area under the curve ratios were favorable for both drugs, at 162+/-113 and 20.6+/-6.0, respectively, for doxorubicin and cisplatin.
  • Doxorubicin levels in the peritoneum were higher than in tumor or normal tissue samples.
  • CONCLUSIONS: Cytoreductive surgery combined with HIIC is an expensive but feasible therapeutic approach for locally advanced abdominal tumors.
  • Because our preliminary findings for local disease control are encouraging, a Phase II study is now advisable to verify the activity of this promising treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Costs and Cost Analysis. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Intraoperative Care. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11900234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Kinderyte R, Alisauskaite L, Juodzbaliene EB, Juozaityte E: [Angiosarcoma of the breast: a case report and literature review]. Medicina (Kaunas); 2006;42(7):580-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcoma of the breast is a rare tumor (makes up 0.5 to 1% of all malignant breast tumors).
  • After surgery the diagnosis of hematoma was made.
  • After review of histopathology slides the likely diagnosis of angiosarcoma of the breast was made.
  • The effect of chemotherapy and radiotherapy was only partial and short.
  • The tumor extended further to the lungs, pleura, and peritoneum.
  • A patient from the time of diagnosis survived for 8 months.
  • The mean survival of patients with angiosarcoma of the breast, described in literature, ranges from 13 to 22 months, and the treatment in this case most likely could not have an effect on survival of the patient.
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Mastectomy, Simple. Prognosis. Radiography, Thoracic. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861841.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


3. Prokopchuk OL, Zemskov SV, Susak YM: Ukrain treatment of a patient with retroperitoneal synovial sarcoma. Case report. Drugs Exp Clin Res; 2000;26(5-6):255-6
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ukrain treatment of a patient with retroperitoneal synovial sarcoma. Case report.
  • A 23-year-old woman, diagnosed with a synovial sarcoma of the peritoneum, underwent an operation for tumor extraction.
  • Ukrain treatment was well tolerated by the patient and there were no complications in the postoperative period.
  • Nearly 4 years after Ukrain therapy, the patient is in complete remission.
  • [MeSH-major] Alkaloids / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Sarcoma, Synovial / drug therapy
  • [MeSH-minor] Adult. Berberine Alkaloids. Female. Humans. Immunity, Cellular / drug effects. Phenanthridines

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11345034.001).
  • [ISSN] 0378-6501
  • [Journal-full-title] Drugs under experimental and clinical research
  • [ISO-abbreviation] Drugs Exp Clin Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Berberine Alkaloids; 0 / Phenanthridines; 6251Q9UK1S / ukrain
  •  go-up   go-down


Advertisement
4. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, Lise M: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am; 2003 Jul;12(3):781-94
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraperitoneal chemotherapy, mainly when performed during HIIC after cytoreductive surgery, is considered potentially curative for the treatment of solid tumors with spread to the peritoneal surface.
  • When selecting antiblastic agents to be administered intraperitoneally, it is important to bear in mind that a low lipophility and a high molecular weight are the ideal drug characteristics.
  • Drugs with these features allow a favorable ratio to be achieved between peritoneal and plasma concentrations, due to the reduced tendency to diffuse through the plasma-peritoneal barrier, even after extensive removal of the peritoneum.
  • Moreover, a low rate of diffusion through the tumor capillaries implies a low rate of drug clearance, with a higher intratumoral drug accumulation.
  • Among the drugs used so far for intraperitoneal chemotherapy, the combination of CDDP and DXR appears to be one of the most effective available regimens with acceptable local-regional toxicity.
  • In our clinical experience with this drug combination, DXR showed a much more advantageous plasma/peritoneal AUC ratio than CDDP (162 +/- 113 and 20 +/- 6, respectively).
  • Following experimental and clinical results of TNF alpha-based isolated limb perfusion for locally advanced soft tissue sarcoma or melanoma, greater efforts are being made to exploit the potential effect of this cytokine used in association with hyperthermia and other drugs (i.e., CDDP and DXR) suitable for intraperitoneal infusion/perfusion.
  • However, it is not yet clear whether the observed effect of TNF alpha on the peritoneal-plasma barrier, which seems to favor the passage of both drugs into the systemic circulation, is overcome by the positive effect of this agent on drug penetration into tumor.
  • Further pharmacologic studies should be undertaken to clarify whether or not these interactions will be of benefit to the patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Carcinoma / drug therapy. Infusions, Parenteral. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Biological Availability. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Neoplasm Staging. Peritoneum / drug effects. Peritoneum / surgery. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14567031.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 50
  •  go-up   go-down


5. Yan TD, Esquivel J, Carmignani P, Sugarbaker PH: Cytoreduction and intraperitoneal chemotherapy for the management of non-gynecological peritoneal surface malignancy. J Exp Clin Cancer Res; 2003 Dec;22(4 Suppl):109-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreduction and intraperitoneal chemotherapy for the management of non-gynecological peritoneal surface malignancy.
  • Peritoneal surface malignancy can arise from pseudomyxoma peritonei, gastrointestinal carcinoma, abdomino-pelvic sarcoma and peritoneal mesothelioma.
  • In the past, only palliative treatments were offered and the results were poor.
  • We have proposed a new concept in managing patients with peritoneal surface malignancy.
  • It involves an aggressive combined treatment modality of cytoreduction and perioperative intraperitoneal chemotherapy.
  • The results are promising for patients with pseudomyxoma peritonei, peritoneal mesothelioma and well-selected patients with invasive peritoneal surface malignancies.
  • The success in such comprehensive treatment depends on tumor biology, patient's co-morbidities, the completeness of cytoreduction, the efficacy of intraperitoneal chemotherapy administration and the surgeon's experience.
  • Large phase II studies have demonstrated the marked survival advantage in this aggressive approach to peritoneal surface malignancy.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Digestive System Surgical Procedures. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infusions, Intralesional. Infusions, Parenteral. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767916.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


6. Sugarbaker PH: Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol; 2001 Dec;31(12):573-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peritoneal surface malignancy can result from seeding of gastrointestinal cancer or abdomino-pelvic sarcoma; it can also occur as a primary disease, such as peritoneal mesothelioma.
  • METHODS: An aggressive approach to peritoneal surface malignancy involves peritonectomy procedures, perioperative intraperitoneal chemotherapy and knowledgeable patient selection.
  • The clinical assessments necessary for valid clinical judgements include the cancer histopathology (invasive vs expansive progression), the preoperative abdominal and pelvic CT, the peritoneal cancer index and the completeness of cytoreduction score.
  • Proper patient selection is mandatory for optimizing the results of treatment.
  • RESULTS: In a series of phase II studies, appendiceal tumors with peritoneal seeding became the paradigm for success with an 85% long-term survival in selected patients.
  • Peritoneal mesothelioma showed a 36% 5-year survival.
  • In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit.
  • CONCLUSIONS: Oncologists must accept responsibility for knowledgeable management of peritoneal surface dissemination of cancer because a curative approach has been demonstrated in large phase II studies and all historical controls show 0% long-term survival.
  • Adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Gastrointestinal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Humans. Infusions, Parenteral. Mesothelioma / drug therapy. Neoplasm Seeding. Patient Selection. Peritoneum / surgery. Second-Look Surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2001 Dec;31(12):571-2 [11902486.001]
  • (PMID = 11902487.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


7. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon LJ, Sugarbaker PH: Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol; 2002 Feb;28(1):80-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
  • Despite new developments in multi-modality treatments, complete resection remains as an absolute requirement for cure of gastrointestinal cancer.
  • We have reported benefits from combined treatment with complete cytoreduction and intraperitoneal chemotherapy.
  • Success in the surgical management of peritoneal surface malignancy depends on the surgeon's ability to complete complex cytoreductive procedures so that only microscopic residual disease remains.
  • This paper describes the current strategy that the surgical oncologist should pursue in the treatment of patients with peritoneal carcinomatosis, sarcomatosis and mesothelioma.
  • Technical details required for this surgery include patient position, incision and exposure, complete lysis of adhesion, electroevaporative dissection with irrigation and suction to preserve the translucent quality of tissues, peritonectomy procedures, proper positioning of tubes and drains for intraperitoneal chemotherapy, and reconstructive surgery.
  • Understanding the treatment and mastery of surgical skills to manage the peritoneal surface spread of cancer has led to long-term survival of selected patients.
  • Combination of this treatment strategy with proper patient selection has reduced the mortality and morbidity.
  • The success of cytoreductive surgery and perioperative intraperitoneal chemotherapy depends on a long-term dedication to achieve the full potential of a curative outcome.
  • Our unit has continued to achieve good results over two decades as improved results of treatment have evolved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / surgery. Mesothelioma / surgery. Peritoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Cholecystectomy / methods. Colectomy / methods. Combined Modality Therapy. Electrosurgery. Humans. Hyperthermia, Induced. Peritoneal Lavage. Peritoneum / surgery. Postoperative Complications. Reoperation. Splenectomy / methods

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11869020.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Anderson PM, Pearson M: Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep; 2006 Jul;8(4):310-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutic approaches in pediatric and young adult sarcomas.
  • Novel therapy as part of sarcoma treatment schemas can enhance quality of life and is important in improving outcomes of high-risk sarcomas.
  • Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural chemotherapy, aerosol 9-nitrocamptothecin, or protracted irinotecan and temozolomide in Ewing's sarcoma; continuous hyperthermic peritoneal perfusion for malignancy involving the peritoneum, such as desmoplastic small round cell tumor; and ifosfamide with muramyl tripeptide phosphatidyl ethanolamine liposomes in osteosarcoma.
  • These treatments bring improved control of symptoms, including reduction in nausea, mucositis, cardiotoxicity, and central nervous system toxicity.
  • Physical approaches to eliminate sarcoma tumors and metastases are critical for durable responses.
  • Novel local control measures include embolization before surgery, radiosensitization, anti-vascular endothelial growth factor therapy during chemo-radiotherapy, proton therapy, samarium, thermal ablation (radiofrequency ablation), and cryoablation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / therapy
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Humans. Hypothermia, Induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):440-9 [14998846.001]
  • [Cites] Lancet Oncol. 2005 Feb;6(2):93-102 [15683818.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2004-11 [15774791.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] J Surg Res. 2006 Mar;131(1):26-40 [16154153.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):315-20 [15161588.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):677-84 [15289869.001]
  • [Cites] Eur J Oncol Nurs. 2005 Mar;9(1):21-32 [15774338.001]
  • [Cites] Mayo Clin Proc. 2003 Feb;78(2):147-55 [12583525.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3597-604 [15908670.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7135-42 [16192597.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2963-9 [8221562.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):182-90 [15717743.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S68-73 [16399436.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):492-8 [15667972.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):631-6 [7884424.001]
  • [Cites] Int J Colorectal Dis. 1999 Apr;14(2):86-94 [10367253.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Int J Clin Oncol. 2005 Dec;10(6):438-40 [16369750.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Mar;21(2):216-22 [15711216.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):189-93 [12407700.001]
  • [Cites] Radiology. 2005 May;235(2):469-77 [15858089.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1433-9 [9762946.001]
  • [Cites] Support Care Cancer. 2004 Aug;12(8):543-9 [15221580.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1287-94 [16109605.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2316-23 [10499599.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):15-22 [16311108.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6895-900 [16203780.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):171-83 [8875708.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):21-8 [15188662.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Methods Mol Med. 2005;111:127-48 [15911977.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Apr;2(4):196-201 [16264934.001]
  • [Cites] Methods Enzymol. 2005;391:71-97 [15721375.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8 [15838394.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):840-8 [14871959.001]
  • [Cites] Oncology. 2004;67(3-4):231-42 [15557784.001]
  • [Cites] Radiology. 2005 Apr;235(1):289-98 [15798173.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):111-9 [16390599.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):401-6 [15800948.001]
  • [Cites] Nutrition. 2002 Mar;18(3):217-21 [11882392.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):997-1000 [12854901.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9 [16203786.001]
  • (PMID = 17254532.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


9. Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M: Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol; 2005 Nov;12(11):910-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion.
  • Treated pathologies included peritoneal mesothelioma; pseudomyxoma peritonei; colorectal, ovarian, or gastric carcinomatosis; and abdominal sarcomatosis.
  • On univariate analysis we found a statistically significant association between bowel complications and the following variables: sex, previous systemic chemotherapy status, number of anastomoses ( fewer than two vs. two or more), duration of the procedure (<8.7 vs. >or=8.7 hours), and extent of cytoreduction.
  • After multivariate analysis, male sex (odds ratio [OR], 4.2), no previous systemic chemotherapy (OR, 3.5), and duration of the procedure >or=8.7 hours (OR, 6.3) were considered independent risk factors for bowel complications.
  • Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors.
  • [MeSH-major] Hyperthermia, Induced. Intestinal Diseases / etiology. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / therapy. Peritoneum / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Colon / surgery. Combined Modality Therapy. Female. Gastrectomy. Humans. Intestinal Fistula / etiology. Intestines / surgery. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177862.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


10. Kravtsov VG, Zaĭrat'iants OV: [Clinical and morphological characteristics of gastrointestinal stromal tumors]. Arkh Patol; 2007 Sep-Oct;69(5):54-61
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is supported by successful chemotherapy for GIST with a KIT receptor inhibitor.
  • Many GISTs behave like sarcomas and they are characterized by an infiltrating growth, hematogenic (mainly into the liver) and implantational (along the peritoneum) cancer spread.
  • [MeSH-minor] Antigens, CD34 / biosynthesis. Antigens, CD34 / genetics. Apoptosis / genetics. Enzyme Activation / genetics. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Melanoma / genetics. Melanoma / metabolism. Melanoma / pathology. Mitosis / genetics. Mutation. Myocytes, Smooth Muscle / metabolism. Myocytes, Smooth Muscle / pathology. Neoplasm Metastasis. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / genetics. Sarcoma / metabolism. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074824.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 44
  •  go-up   go-down


11. Lobo ED, Balthasar JP: Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. J Pharm Sci; 2005 Sep;94(9):1957-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer.
  • Anti-drug antibodies may be used to impart regio-specific alterations in drug disposition, potentially enhancing the therapeutic selectivity of intracavitary chemotherapy.
  • In the present study, we tested the hypotheses that systemic therapy with anti-methotrexate antibodies would allow increases in the maximum tolerated dose of intraperitoneal methotrexate (MTX) and allow increases in the therapeutic efficacy of intraperitoneal MTX in a murine model of peritoneal cancer.
  • MTX efficacy was investigated in mice bearing peritoneal sarcoma 180 tumors, following administration of MTX via 72 h i.p. infusion at 1.9, 2.8, 3.8 mg/kg, and following combination therapy of 7.5 or 10 mg/kg i.p.
  • In mice bearing peritoneal tumors, the maximally tolerated dose of i.p.
  • Median survival times for saline-treated control animals and animals receiving i.p.
  • However, for animals receiving combination therapy with i.p.
  • AMF, median survival time increased to 17 and 14 days, respectively.
  • MTX, and allow increases in the therapeutic efficacy of i.p.
  • MTX chemotherapy of peritoneal tumors.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Immunoglobulin Fab Fragments / pharmacology. Methotrexate / therapeutic use. Peritoneal Neoplasms / drug therapy. Sarcoma 180 / drug therapy
  • [MeSH-minor] Animals. Area Under Curve. Body Weight / drug effects. Combined Modality Therapy. Disease Models, Animal. Half-Life. Injections, Intraperitoneal. Injections, Intravenous. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Mice. Survival Rate

  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052545.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antimetabolites, Antineoplastic; 0 / Immunoglobulin Fab Fragments; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS: Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
  • In the era of kit immunohistochemistry and imatinib mesylate therapy the outcome of IASs is unknown.
  • METHODS: We analyzed 268 consecutive patients who were referred to our institution for evaluation of the diagnosis of GIST from 12/15/00 to 9/1/01.
  • Patients diagnosed with GIST were treated with imatinib mesylate, and patients diagnosed with other IAS were treated with standard sarcoma chemotherapy.
  • A single sarcoma pathologist reviewed all patients' tumor blocks.
  • RESULTS: Of 268 patients, 4 patients were excluded because of diagnoses other than sarcoma.
  • Another 46 patients were excluded because no data were available at the time of this abstract.
  • Of the remaining 218 patients, 159 (72.9%) were GIST and 59 (27.1%) were IAS specifically: 31 leiomyosarcoma, 10 spindle cell tumors, 4 unclassified sarcomas, and 14 other types of sarcoma.
  • The most common metastatic sites seen in patients with GIST were liver (68.6%) and peritoneum (51.6%); whereas other IASs metastasized to the liver (39%) and peritoneum (30.5%).
  • While median survival from the time of diagnosis has not been reached in patients with GIST, in other IAS median survival is 63.8 months.
  • Time to progression in patients with GIST was 16.4 months after imatinib and 5.1 months in patients with IAS treated with standard sarcoma chemotherapy.
  • CONCLUSIONS: Survival and time to progression are worse for IAS compared to GISTs.
  • New therapies for these tumors are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Casali PG, Stacchiotti S, Palassini E, Marrari A, Negri T, Morosi C, Messina A, Pastorino U, Gronchi A, Pilotti S: Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT). J Clin Oncol; 2009 May 20;27(15_suppl):10571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10571 Background: SFT is a rare soft tissue tumor, with an unpredictable metastatic potential.
  • When medical therapy is needed, cytotoxic chemotherapy is poorly active in this sarcoma subtype, but the activity of bevacizumab + temozolomide was recently reported.
  • METHODS: From April 2008, 5 patients with progressive metastatic SFT resistant to conventional chemotherapy (male/female: 3/2 - mean-age: 58 years - PS: 0-3 - site: peritoneum 3, pleura 1, bladder 1) have been treated with continuous-dosing SM 37.5 mg/day, on an individual use basis.
  • All patients were evaluated for response at least once, while 2 more patients are now starting therapy.
  • The other patient stopped therapy for progression after 3 weeks and died 2 weeks later.
  • One responsive patient stopped therapy after 3 weeks for side effects and depression.
  • The remaining 3 responsive patients are currently on treatment, although one had a focal progression after 9 months.
  • This might help address an unmet clinical need in a rare sarcoma subtype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Macák J, Mukensnábl P, Kawano N, Bobot L, Dusková M, Vácha P: [Intra-abdominal desmoplastic small-cell tumor of the peritoneum]. Cesk Patol; 2003 Apr;39(2):69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoplastic small-cell tumor of the peritoneum].
  • [Transliterated title] Intraabdominální dezmoplastický malobunĕcný nádor peritonea.
  • The authors described three cases of intraabdominal desmoplastic small round cell tumour of the peritoneum (IDSRT).
  • Intensive chemotherapy was applied but two patients died of generalisation.
  • The "classical" type of IDSRT was found in all the cases.
  • Many different tumour types, such as lymphoma, Ewing sarcoma/PNET, neuroblastoma, alveolar rhabdomyosarcoma, malignant mesothelioma must be excluded.
  • [MeSH-major] Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874904.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


15. Pinto Marín A, Garrido Arévalo M, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, González Barón M: Intra-abdominal desmoplastic small round cell tumour in a 39-year-old man. Clin Transl Oncol; 2009 Nov;11(11):770-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no standard therapy, and responses to chemotherapy are infrequent.
  • Surgery is still the main treatment for this disease.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Sarcoma, Small Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Neoplasm Metastasis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneum. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Mar;210(3):633-8 [10207460.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Indian J Cancer. 2005 Apr-Jun;42(2):78-84 [16141506.001]
  • [Cites] Eur J Radiol. 2005 Jun;54(3):438-42 [15899348.001]
  • [Cites] Surg Oncol. 2008 Aug;17(2):107-12 [18191563.001]
  • [Cites] Clin Nucl Med. 1999 Sep;24(9):693-4 [10478748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):413-21 [2469334.001]
  • [Cites] J Pediatr Surg. 2005 Jan;40(1):251-5 [15868593.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):170-6 [12182988.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):646-9 [17425400.001]
  • [Cites] Eur J Pediatr Surg. 2006 Dec;16(6):423-7 [17211792.001]
  • [Cites] Oncology. 2004;67(3-4):231-42 [15557784.001]
  • [Cites] J Comput Assist Tomogr. 2002 Jul-Aug;26(4):579-83 [12218823.001]
  • (PMID = 19917543.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Orsey A, Paessler M, Lange BJ, Nichols KE: Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer; 2008 Apr;50(4):927-30
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile xanthogranuloma (JXG) is a rare histiocytic disorder that typically manifests in the skin.
  • Here, we describe a patient with JXG diffusely involving the central nervous system (CNS), whose disease responded to therapy but subsequently underwent dissemination to the peritoneum and bone marrow.
  • Despite further chemotherapy, the patient died of disease progression.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Histiocytic Sarcoma / pathology. Xanthogranuloma, Juvenile / physiopathology. Xanthogranuloma, Juvenile / therapy
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Diseases / pathology. Child. Cladribine / therapeutic use. Dexamethasone / therapeutic use. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Pseudotumor Cerebri / pathology. Radiotherapy


17. Deraco M, Gronchi A, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M: Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. Tumori; 2002 Sep-Oct;88(5):370-5
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: Pseudomyxoma peritonei is a rare disease characterized by a complete redistribution of mucin within the peritoneal cavity.
  • It can be classified into three histologic groups: disseminated peritoneal adenomucinosis, peritoneal mucinous carcinomatosis, and an intermediate group.
  • The aim of the present study was to evaluate the feasibility of cytoreductive surgery requiring peritonectomy procedures associated with intraperitoneal hyperthermic perfusion, a technique that combines hyperthermia and high drug doses administered locally.
  • All patients with peritoneal mucinous carcinomatosis presented serous ascites, whereas all but one patient with disseminated peritoneal adenomucinosis or in the intermediate group presented mucinous ascites.
  • RESULTS: All but one of the patients with disseminated peritoneal adenomucinosis and 2 of the 3 patients in the intermediate group were optimally cytoreduced.
  • Patients with serous ascites (all patients with peritoneal mucinous carcinomatosis and 1 patient with disseminated peritoneal adenomucinosis) were considered ineligible for treatment because of tumor diffusion.
  • There was one case of treatment-related mortality 30 days after treatment.
  • 1) patients with pseudomyxoma peritonei originating from undifferentiated mucinous adenocarcinoma (peritoneal mucinous carcinomatosis), with complete distribution into the peritoneal cavity, are not eligible for the cytoreductive surgery plus intraperitoneal hyperthermic perfusion technique;.
  • 2) the presence of serous ascites would seem to exclude patients from the treatment;.
  • 3) cytoreductive surgery associated with intraperitoneal hyperthermic perfusion is the most suitable approach for patients with disseminated peritoneal adenomucinosis and in the intermediate group.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Peritoneum / surgery. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Infusions, Parenteral / methods. Male. Middle Aged. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487553.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Danikas D, Theodorou SJ, Singh R, Camal DE: Leiomyosarcoma of the gallbladder: a case report. Am Surg; 2001 Sep;67(9):873-4
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sarcoma of the gallbladder is a rare disease.
  • The diagnosis is rarely made preoperatively.
  • Laparoscopic cholecystectomy was converted to open as a result of dense tissue in the middle to distal gallbladder.
  • Exploration by a right subcostal incision revealed multiple implants on the surface of the liver and the peritoneum of the upper abdomen.
  • The disease followed a very aggressive course and the patient died 3 weeks after the procedure.
  • Recommended treatment is extensive surgical resection that can be followed by radiotherapy or chemotherapy.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Gallbladder / pathology. Humans. Liver / pathology. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11565767.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Salemis NS, Gourgiotis S, Tsiambas E, Panagiotopoulos N, Karameris A, Tsohataridis E: Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor. J Gastrointest Cancer; 2010 Dec;41(4):238-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life occurring predominantly in the extremities.
  • Computed tomography (CT) scan demonstrated a mass in the right iliac fossa.
  • RESULTS: On exploratory laparotomy, a tumor was found in the right iliac fossa attached to the parietal lateral peritoneum without any evidence of invasion into the adjacent structures.
  • One month after surgery, while on adjuvant chemotherapy, the patient was readmitted with dyspnea and a slightly palpable mass in the area of the previous radical resection.
  • Unfortunately, despite treatment, the patient died of progressive disease 5 weeks later.
  • Early detection and complete surgical excision with clear margins is the treatment of choice.
  • In some cases, however, the tumor can exhibit a highly aggressive clinical course despite radical surgery and adjuvant therapy.
  • [MeSH-major] Abdomen / pathology. Histiocytoma, Malignant Fibrous / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):499-505 [1845950.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2098-103 [1311983.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1299-302 [17451221.001]
  • [Cites] Gastrointest Radiol. 1988 Oct;13(4):299-305 [2844619.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Surg Today. 2003;33(10 ):794-6 [14513333.001]
  • [Cites] Surg Today. 2002;32(12):1091-5 [12541030.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] World J Gastroenterol. 2007 Dec 21;13(47):6441-3 [18081238.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Clin Imaging. 1998 Nov-Dec;22(6):408-13 [9876909.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Dig Surg. 1999;16(5):425-30 [10567806.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 22;3:15 [16792809.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):105-12 [16648661.001]
  • (PMID = 20419356.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • We performed exploratory laparotomy and found at least 15 solid whitish tumors attached to the wall of the small intestine, as well as to the parietal peritoneum.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Li J, Stickel SL, Bouton-Verville H, Burgin KE, Yu X, Wong DK, Wagner TE, Wei Y: Fermented Noni exudate (fNE): a mediator between immune system and anti-tumor activity. Oncol Rep; 2008 Dec;20(6):1505-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we studied the anti-tumor activity of fermented Noni exudate (fNE) and demonstrated that intraperitoneal injection of this material significantly increased the percentages of granulocytes and NK cells in the peripheral blood, peritoneum, and spleen.
  • Furthermore, in preventive and treatment settings, fNE injection induced complete tumor rejection in normal C57BL/6J mice, partial tumor rejection in C57 nude mice lacking functional lymphocytes, and no tumor rejection in NK cell deficient beige mice.
  • [MeSH-minor] Animals. Ascites / metabolism. Female. Fermentation. Fruit / metabolism. Immune System. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Nude. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020734.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


22. Athanasiou A, Vanel D, El Mesbahi O, Theodore C, Fizazi K: Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings. Eur J Radiol; 2009 Feb;69(2):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had computed tomography (CT) and/or magnetic resonance (MR) studies before and after initial surgery and chemotherapy, as well as during follow-up.
  • Imaging findings were correlated with the response to treatment and with overall survival.
  • Sarcoma was identified in 10 out of 14 patients, with rhabdomyosarcoma ranking first (n=4), followed by osteosarcoma (n=2), fusiform cell sarcoma (n=1), undifferentiated sarcoma (n=1), neurosarcoma (n=1) and myxoid sarcoma (n=1).
  • Other histological types of malignant transformation included adenocarcinoma (n=3) and bronchoalveolar carcinoma (n=1).
  • Overall, 9 patients relapsed at a median time of 84 months (range 60-168).
  • RESULTS: Non-GCT malignant transformation was identified in the retroperitoneum (5), testis (3), mediastinum (3), peritoneum (2) and lungs (1).
  • The CT and MR imaging findings before treatment and after relapse were evaluated with emphasis on imaging features that could possibly imply the presence of malignant transformation (heterogeneously enhancing soft-tissue masses, ossified masses with calcified lymph nodes, diffuse epiploic thickening associated with ascites and peritoneal nodules, pulmonary alveolar infiltration with septal thickening).
  • Imaging can be useful as CT and MR findings may suggest this entity and lead to an early biopsy and appropriate treatment.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Magnetic Resonance Imaging. Teratoma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056194.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


23. Vulcan TG, Zhu TC, Rodriguez CE, Hsi A, Fraker DL, Baas P, Murrer LH, Star WM, Glatstein E, Yodh AG, Hahn SM: Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med; 2000;26(3):292-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy.
  • BACKGROUND AND OBJECTIVE: On-line monitoring of light fluence during intraperitoneal photodynamic therapy (IP PDT) is crucial for safe light delivery.
  • Tissue phantom experiments were performed to provide a preliminary estimate of the tissue optical properties of the peritoneum.
  • The mu(eff) of the tissues in the abdomen is estimated to vary between 0.5 cm(-1) to 1.4 cm(-1) assuming a mu(s)' = 7 cm(-1).
  • Differences in the optical properties of the underlying tissues may contribute to the variability in light measurements.
  • [MeSH-major] Dihematoporphyrin Ether / administration & dosage. Gastrointestinal Neoplasms / drug therapy. Hematoporphyrin Photoradiation / methods. Ovarian Neoplasms / drug therapy. Photosensitizing Agents / administration & dosage. Sarcoma / drug therapy. Thermoluminescent Dosimetry / instrumentation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10738292.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down






Advertisement